Ascendis Pharma A/S (ASND): Price and Financial Metrics


Ascendis Pharma A/S (ASND)

Today's Latest Price: $136.97 USD

3.03 (-2.16%)

Updated Jul 10 4:00pm

Add ASND to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

ASND Stock Summary

  • ASND's price/sales ratio is 442.27; that's higher than the P/S ratio of 99% of US stocks.
  • Over the past twelve months, ASND has reported earnings growth of 593.37%, putting it ahead of 97.5% of US stocks in our set.
  • As for revenue growth, note that ASND's revenue has grown 62% over the past 12 months; that beats the revenue growth of 91.48% of US companies in our set.
  • Stocks that are quantitatively similar to ASND, based on their financial statements, market capitalization, and price volatility, are FATE, QURE, AUTL, ARNA, and CRNX.
  • ASND's SEC filings can be seen here. And to visit Ascendis Pharma A's official web site, go to www.ascendispharma.com.
ASND Daily Price Range
ASND 52-Week Price Range

ASND Stock Price Chart Technical Analysis Charts


ASND Price/Volume Stats

Current price $136.97 52-week high $158.93
Prev. close $140.00 52-week low $90.06
Day low $135.51 Volume 275,078
Day high $143.12 Avg. volume 225,305
50-day MA $143.41 Dividend yield N/A
200-day MA $126.16 Market Cap 6.57B

Ascendis Pharma A/S (ASND) Company Bio


Ascendis Pharma A/S is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained release technologies, to develop a pipeline of best-in-class therapeutics that address significant unmet medical needs. The company was founded in 2006 and is based in Hellerup, Denmark.


ASND Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ASND Latest Social Stream


Loading social stream, please wait...

View Full ASND Social Stream

Latest ASND News From Around the Web

Below are the latest news stories about Ascendis Pharma A that investors may wish to consider to help them evaluate ASND as an investment opportunity.

Did Hedge Funds Make The Right Call On Ascendis Pharma A/S (ASND) ?

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]

Yahoo | July 11, 2020

Ascendis Pharma prices ADS offering at $142

Ascendis Pharma (ASND) has priced its public offering of 4,225,352 American Depositary Shares (ADSs), each of which represents one ordinary share, at a price of $142.00/ ADS.Underwriters' over-allotment is an additional 633,802 ADSs.Estimated net proceeds of ~$569.2M will be used to support the clinical development of product candidates and clinical...

Seeking Alpha | July 8, 2020

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced the pricing of its underwritten public offering of 4,225,352 American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis, at a price to the public of $142.00 per ADS. All of the ADSs are being offered by Ascendis. In addition, Ascendis has granted the underwriters a 30-day option to purchase up to an additional 633,802 ADSs at the public offering price, less the underwriting commissions.

Yahoo | July 8, 2020

Ascendis Pharma initiates capital raise

Ascendis Pharma ([[ASND]] +1.5%) commences an underwritten public offering of $500M of American Depositary Shares ((ADSs)) with 30-day underwriters option to purchase up to an additional $75M of ADSs at the public offering price.Price, volume and terms have yet to be disclosed....

Seeking Alpha | July 6, 2020

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

Ascendis Pharma A/S (ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address unmet medical needs, today announced that it has commenced an underwritten public offering of $500,000,000 of American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis. All of the ADSs are being offered by Ascendis. In addition, Ascendis expects to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 of ADSs at the public offering price, less the underwriting commissions.

Yahoo | July 6, 2020

Read More 'ASND' Stories Here

ASND Price Returns

1-mo -1.90%
3-mo 8.11%
6-mo -1.60%
1-year 21.57%
3-year 387.61%
5-year 556.30%
YTD -1.55%
2019 122.06%
2018 56.39%
2017 97.92%
2016 10.48%
2015 N/A

Continue Researching ASND

Want to see what other sources are saying about Ascendis Pharma A's financials and stock price? Try the links below:

Ascendis Pharma A (ASND) Stock Price | Nasdaq
Ascendis Pharma A (ASND) Stock Quote, History and News - Yahoo Finance
Ascendis Pharma A (ASND) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8003 seconds.